Newsroom
Discover the latest news and updates from Almirall.
Quick Links
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
Discover the latest news and updates from Almirall.
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
560 results
Published on 5 June 2026
At Almirall, improving the lives of patients goes hand in hand with protecting the environment we all share. This World Environment Day, we want to reinforce our commitment to taking decisive climate action on our path to becoming a net-zero emissions company by 2050.
But 2050 is built on the choices we make today. We are already making tangible progress through real, measurable actions. Our operational sites across Spain and Germany have been running on 100% renewable electricity since 2018, and in 2025 we reduced our direct greenhouse gas emissions by 22%, keeping us firmly on track to achieve our 50% reduction target by 2030.
We are also strengthening our approach to water management, having already reduced our consumption by 20% from our baseline, with the ambition to reach a 25% reduction by 2030. These efforts are helping us build greater resilience in the face of climate-related risks.
Our progress has been externally recognised, with Almirall named among Europe’s Climate Leaders 2026 by the Financial Times and Statista for the third consecutive year.
Every action we take brings us one step closer to a more sustainable future — for our patients, our communities and the planet we all share.
Published on 1 June 2026
During Hidradenitis Suppurativa Awareness Week, we want to shed light on a chronic, painful and often misunderstood condition that goes far beyond the skin. Hidradenitis suppurativa (HS) is a non-contagious inflammatory disease characterized by painful nodules, abscesses and, in some cases, scarring, which can significantly impact patients’ quality of life and daily routines.
Beyond its physical symptoms, HS carries a substantial emotional and psychological burden. Persistent pain, together with stigma and a lack of awareness, can affect sleep, confidence, mental health and overall well-being, often making the invisible impact of the disease as challenging as the visible one. For many people living with HS, managing the condition also means navigating uncertainty and the feeling of not being fully understood.
Raising awareness is essential to improving understanding, encouraging earlier diagnosis and reducing stigma. Greater knowledge of the disease can help patients seek the care they need and support a more timely and accurate diagnosis, while also fostering a more empathetic and informed society.
At Almirall, we remain committed to advancing innovation in medical dermatology and to developing solutions that make a meaningful difference for people living with HS, with a clear focus on addressing both the physical and emotional impact of the disease.
Published on 28 May 2026
We’re proud to be recognised for the third consecutive year as one of Europe’s Climate Leaders by the Financial Times and Statista. This recognition reflects the consistent effort we’ve made to turn environmental ambition into tangible results, embedding sustainability into the core of our business.
Over the past years, we have continued to strengthen how we measure and manage our environmental impact, integrating sustainability considerations across decision-making processes, operations, and innovation. This ongoing work allows us not only to track progress more effectively, but also to identify new opportunities to reduce our footprint and contribute positively to the communities and ecosystems we are part of.
Driving real progress means going beyond commitments—it requires measurable action, long-term vision, and continuous improvement. That’s why we remain focused on aligning our corporate strategy with science-based goals, ensuring that every step we take contributes to a more sustainable future.
This milestone is not just about recognition, but about reinforcing our responsibility to keep moving forward.
Published on 24 May 2026
On AK Global Day, we launched Skin Scouts, a global awareness initiative designed to reinforce the importance of early detection in medical dermatology. The campaign encourages everyone to look closer at their skin and recognize early warning signs that often go unnoticed, helping transform awareness into timely and meaningful action.
Actinic keratosis is a common condition that can act as an early warning sign of skin cancer. Too often, these lesions are mistaken for harmless skin changes linked to ageing or sun exposure. That is why, on AK Global Day, we proudly launch the #AKSkinScouts initiative to remind people that paying attention early can make a critical difference for long-term skin health.
Built around three simple steps — observe, detect, and act — Skin Scouts aims to empower the general public with practical knowledge. The campaign encourages regular skin observation, greater awareness of rough or scaly patches in sun-exposed areas, and a better understanding of key risk factors such as chronic sun exposure and skin type.
By combining education, awareness, and a clear call to action, Skin Scouts promotes a proactive approach to skin health and shared responsibility. Through engaging content and simple gestures, the initiative invites everyone to sharpen their focus, join the movement, and help spread a message that can lead to earlier detection and better outcomes.
Published on 18 May 2026
Press release
PDF 329.3KB
Published on 11 May 2026
Press release
PDF 209.9KB
Published on 11 May 2026
Today, we shared our financial results for the first quarter of 2026, continuing our positive trajectory and delivering performance in line with expectations and our long-term growth strategy.
This first quarter marks another step forward in our growth journey, supported by the strong momentum of our European Dermatology business, which grew by 19.3% year-on-year, reaching €166.3 MM. Overall, total Net Sales increased by 2.2% year-on-year to €291 MM, representing a 9% increase on a last twelve months (LTM) basis. These results reflect the consistency of our performance and the strength of the foundations we continue to build.
Our growth continues to be driven by the solid performance of our biologics portfolio and the sustained contribution of our broader dermatology portfolio, reinforcing our position in medical dermatology and supporting long-term value creation.
Profitability also showed a positive evolution, with total EBITDA reaching €67.5 MM, representing 23.2% of Net Sales and an improvement compared to the previous year. This reflects our ongoing focus on operational efficiency and disciplined execution across the business.
During the quarter, we also continued to advance our R&D pipeline, reinforcing our commitment to long-term innovation. Key milestones included the initiation of a new Phase I study and the announcement of a new strategic R&D collaboration, further strengthening our scientific capabilities and future growth potential.
Looking ahead, we remain focused on executing our strategy and sustaining our growth momentum. Our outlook for the full year 2026 remains unchanged, with expected Net Sales growth of 9–12% and EBITDA in the range of €270 MM to €290 MM.
As we continue to deliver on our strategy, we remain committed to transforming today’s science into meaningful solutions for people living with skin conditions.
Published on 8 May 2026
Today, we held our Annual General Meeting of Shareholders, reflecting on our continued momentum and steady progress toward our ambition of becoming a global leader in medical dermatology. The meeting provided an update on our performance, strategic priorities, and the key drivers shaping our growth trajectory.
Our strong performance is driven by the solid evolution of our European Dermatology business and the continued expansion of our biologics portfolio. These pillars, together with the advancement of our R&D pipeline, are reinforcing our position and supporting long-term value creation.
A key highlight of the meeting was our transition into a new phase of sustained double-digit growth and margin expansion starting in 2025. This progress reflects our continuous investment in strengthening capabilities across the entire value chain—from research and development to manufacturing and commercial operations—enabling consistent performance and building a strong foundation for future growth.
Looking ahead, we are well positioned to maintain this momentum, supported by a robust pipeline and important R&D milestones expected throughout the year. These advancements will continue to drive innovation and bring new solutions to patients.
The meeting also underscored our commitment to our purpose of transforming the lives of people living with skin conditions. By combining scientific excellence, innovation, and a clear strategic focus, we continue to advance medical dermatology while delivering sustainable growth.
We thank our shareholders for their continued trust and support, which remain key to advancing our long-term vision.
Published on 30 April 2026
Today, we launch Almirall’s 2025 Year in Review, a comprehensive publication that looks back on a transformative year and captures the key achievements that shaped our progress throughout 2025. The Year in Review offers a structured and transparent overview of a year defined by accelerated growth, strategic clarity, and a strengthened leadership position in medical dermatology.
Throughout 2025, we continued to advance our growth trajectory in line with our ambition to lead medical dermatology. The Year in Review reflects how this ambition translated into concrete results: the continued expansion of a differentiated dermatology portfolio, steady progress across an exciting R&D pipeline of innovative assets, and strong commercial execution. Together, these elements enabled us to meet our financial guidance while delivering sustained double‑digit sales growth and margin expansion.
Beyond performance, the 2025 Year in Review provides a broader perspective on the drivers behind these results. Readers will find an overview of the year, together with the major milestones that marked the year and a letter from our CEO outlining the strategic context and long‑term direction. The publication also explores how we continue transforming patients’ lives through our portfolio and key products, and how close partnerships with dermatologists remain central to our approach.
In addition, the Year in Review includes a detailed chapter on our financial performance, complemented by insights into our financial outlook and stock performance. It also highlights our focus on innovation as a key enabler of sustainable growth, alongside our continued commitment to sustainability and to the principles of corporate governance that guide responsible decision‑making and long‑term value creation.
By bringing together business results, strategy, innovation, and impact, the 2025 Year in Review captures how 2025 laid solid foundations for the future and reinforces our commitment to advancing medical dermatology through science, innovation, and partnerships.
Published on 13 April 2026
Press release
PDF 91.5KB
